Steve Aselage Travere Therapeutics, Inc. (TVTX) insider trading activity

TVTX Quotes by TradingView

Steve Aselage is Director of Travere Therapeutics, Inc.. Currently has a direct ownership of 146,919 shares of TVTX, which is worth approximately $2.61 Million. The most recent transaction as insider was on May 11, 2022, when has been sold 2,575 shares (Common Stock) at a price of $21.92 per share, resulting in proceeds of $56,444. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 147K
0% 3M change
0% 12M change
Total Value Held $2.61 Million

STEVE ASELAGE Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 11 2022
SELL
Open market or private sale
$56,444 $21.92 p/Share
2,575 Reduced 1.72%
146,919 Common Stock
Nov 16 2021
SELL
Open market or private sale
$934,602 $29.39 p/Share
31,800 Reduced 17.54%
149,494 Common Stock
Nov 05 2021
SELL
Open market or private sale
$262,300 $26.23 p/Share
10,000 Reduced 5.82%
161,794 Common Stock
Nov 05 2021
BUY
Exercise of conversion of derivative security
$162,300 $16.23 p/Share
10,000 Added 5.5%
171,794 Common Stock
Oct 07 2021
SELL
Open market or private sale
$1,575,000 $26.25 p/Share
60,000 Reduced 24.02%
189,794 Common Stock
Oct 07 2021
BUY
Exercise of conversion of derivative security
$973,800 $16.23 p/Share
60,000 Added 19.37%
249,794 Common Stock
Jul 16 2021
SELL
Bona fide gift
-
3,000 Reduced 1.82%
161,794 Common Stock
May 14 2021
BUY
Grant, award, or other acquisition
-
3,000 Added 1.56%
189,794 Common Stock
May 11 2021
SELL
Open market or private sale
$42,019 $19.58 p/Share
2,146 Reduced 1.14%
186,794 Common Stock
Apr 16 2021
SELL
Open market or private sale
$262,300 $26.23 p/Share
10,000 Reduced 5.03%
188,940 Common Stock
Apr 16 2021
BUY
Exercise of conversion of derivative security
$162,300 $16.23 p/Share
10,000 Added 4.79%
198,940 Common Stock
Mar 17 2021
SELL
Open market or private sale
$486,783 $27.46 p/Share
17,727 Reduced 8.58%
188,940 Common Stock
Mar 17 2021
BUY
Exercise of conversion of derivative security
$162,300 $16.23 p/Share
10,000 Added 4.62%
206,667 Common Stock
Feb 04 2021
SELL
Bona fide gift
-
25,000 Reduced 13.17%
164,794 Common Stock
Feb 02 2021
SELL
Open market or private sale
$768,750 $30.75 p/Share
25,000 Reduced 11.28%
196,667 Common Stock
Feb 02 2021
BUY
Exercise of conversion of derivative security
$252,250 $10.09 p/Share
25,000 Added 10.14%
221,667 Common Stock
Dec 15 2020
SELL
Open market or private sale
$144,385 $26.02 p/Share
5,549 Reduced 2.74%
196,667 Common Stock
Dec 02 2020
SELL
Open market or private sale
$184,886 $23.43 p/Share
7,891 Reduced 3.76%
202,216 Common Stock
Nov 19 2020
SELL
Bona fide gift
-
3,000 Reduced 1.41%
210,107 Common Stock
Nov 06 2020
SELL
Open market or private sale
$474,375 $23.0 p/Share
20,625 Reduced 8.82%
213,107 Common Stock
Nov 05 2020
SELL
Open market or private sale
$53,150 $21.26 p/Share
2,500 Reduced 1.06%
233,732 Common Stock

Also insider at

BCRX
BIOCRYST PHARMACEUTICALS INC Healthcare
Director
ACER
Acer Therapeutics Inc. Healthcare
Director
SA

Steve Aselage

Director
Durham, NC

Track Institutional and Insider Activities on TVTX

Follow Travere Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TVTX shares.

Notify only if

Insider Trading

Get notified when an Travere Therapeutics, Inc. insider buys or sells TVTX shares.

Notify only if

News

Receive news related to Travere Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on TVTX